A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004486-17

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective: To define the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of CP-751,871 in adolescents (10-18 years). Phase 2 To define the efficacy of CP-751,871, in terms of objective response rate, in patients with relapsed/refractory Ewing’s sarcoma family of tumors.


Critère d'inclusion

  • Ewing's sarcoma family tumours